Trial Details

Not Recruiting
Basic Information
Clinical ID c3029
Identifier NL-OMON42154
Trial Title Precision dosing of infliximab (IFX): the efficacy and economic effect of *precision dosing* of maintenance treatment with IFX in comparison with standard IFX maintenance treatment in inflammatory bowel disease. - Precision dosing of infliximab
Trial URL Visit Original Page
Study Information
Study Results

No results available
Conditions IBD Inflammatory Bowel disease;10017969
Interventions Patients in the intervention arm will receive individualized treatment with variable IFX dosing AND/OR intervals guided by a Bayesian pharmacokinetic model, aiming to achieve an IFX TL of 3 mg/ml. Patients in the control group will continue to receive the same IFX treatment regimen that was given prior to inclusion without dose adaptation. In the control group, treatment adjustments will only be made in case of signs of active disease, in accordance to current routine care but these patients will be considered as failures to their treatment.
Participant Information
Sponsor Academisch Medisch Centrum
City -
Country/Region Netherlands
Enrollment Criteria
Sex Requirement NOT SPECIFIED
Age Requirement ADULT, ELDER, OLDER_ADULT
Study Design
Study Type Interventional
Phase Not Available
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -